Hoth Therapeutics Inc HOTH

NAS: HOTH | ISIN: US44148G1058   30/04/2025
0,899 USD (+5,64%)
(+5,64%)   30/04/2025

17 april 2025 · Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform · Persbericht

15 april 2025 · Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial · Persbericht

2 april 2025 · Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ · Persbericht

2 april 2025 · Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours · Persbericht

31 maart 2025 · Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage · Persbericht

26 maart 2025 · Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation · Persbericht

18 maart 2025 · Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment · Persbericht

10 maart 2025 · Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need · Persbericht

5 maart 2025 · Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting · Persbericht

4 maart 2025 · Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease · Persbericht

5 september 2024 · Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial · Persbericht

5 september 2024 · Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001 · Persbericht

15 augustus 2024 · Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic · Persbericht

24 juli 2024 · Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment · Persbericht

16 juli 2024 · Hoth Therapeutics Expands Clinical Trial for Cancer Patients · Persbericht

10 juni 2024 · Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery · Persbericht

1 mei 2024 · Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024 · Persbericht

27 maart 2024 · Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds · Persbericht

27 maart 2024 · Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment · Persbericht

19 maart 2024 · Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ · Persbericht

Mijn selecties